Jenny Horne examines earnings figures from biotech giant Moderna (MRNA). The company reported a 4Q loss as it continues to reposition itself following monumental gains during the heights of the COVID-19 pandemic. Jenny points to the company's pipeline as a hopeful catalyst, as Moderna develops infectious disease and oncology treatments.